BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8712822)

  • 1. [Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
    Akutsu M; Suzuki K; Tsunoda S; Kano Y
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):297-302. PubMed ID: 8712822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP; Urben CM; Strugnell SA; Knutson JC
    Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of SN-38 in combination with other anticancer agents against Dauji cells].
    Akutsu M; Suzuki K; Tsunoda S; Kano Y; Miura Y
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1607-11. PubMed ID: 8060135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
    Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line.
    Kano Y; Suzuki K; Akutsu M; Suda K
    Leukemia; 1992 May; 6(5):440-5. PubMed ID: 1593909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines.
    Kano Y; Akutsu M; Suzuki K; Yoshida M
    Leuk Res; 1993 Feb; 17(2):113-9. PubMed ID: 8429687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
    Akutsu M; Furukawa Y; Tsunoda S; Izumi T; Ohmine K; Kano Y
    Leukemia; 2002 Sep; 16(9):1808-17. PubMed ID: 12200697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines].
    Nagasawa M; Ishii S; Kariya Y; Itoh O; Yamamoto H; Kawaharajo K; Takeuchi T
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):633-8. PubMed ID: 2108612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.
    Kano Y; Ohnuma T; Okano T; Holland JF
    Cancer Res; 1988 Jan; 48(2):351-6. PubMed ID: 3422052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
    Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of cisplatin, carboplatin, etoposide and human hepatocyte growth factor on the colony formation of four human liver cancer cell lines].
    Seshimo K; Hamasaki K; Gohda E; Orita K; Namba M
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1967-72. PubMed ID: 8215470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin.
    Meczes EL; Pearson AD; Austin CA; Tilby MJ
    Br J Cancer; 2002 Feb; 86(3):485-9. PubMed ID: 11875719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
    Perez EA; Buckwalter CA; Reid JP
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro effect of combined use of BH-AC and nitrosourea derivatives against adriamycin-resistant human leukemia cell line].
    Oguro M; Sakai C; Takagi T; Matsuura Y
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2403-8. PubMed ID: 1952959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).
    Tsai CM; Gazdar AF; Venzon DJ; Steinberg SM; Dedrick RL; Mulshine JL; Kramer BS
    Cancer Res; 1989 May; 49(9):2390-7. PubMed ID: 2706626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.